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Abstract
Background: Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer therapy
approvals. The aim of this review was to evaluate the methodology of HRQoL analysis and reporting in phase III
clinical trials of first-line chemotherapy in advanced non-small cell lung cancers (NSCLC).
Methods: A search in MEDLINE databases identified phase III clinical trials in first-line chemotherapy for advanced
NSCLC, published between January 2008 to December 2014. Two authors independently extracted information
using predefined data abstraction forms.
Results: A total of 55 phase III advanced NSCLC trials were identified. HRQoL was declared as an endpoint in 27
studies (49 %). Among these 27 studies, The EORTC questionnaire Quality of Life Questionnaire C30 was used in 13
(48 %) of the studies and The Functional Assessment of Cancer Therapy-General was used in 12 (44 %) trials. The
targeted dimensions of HRQoL, the minimal clinically important difference and the statistical approaches for dealing
with missing data were clearly specified in 13 (48.1 %), 9 (33.3 %) and 5 (18.5 %) studies, respectively. The most
frequent statistical methods for HRQoL analysis were: the mean change from baseline (33.3 %), the linear mixed
model for repeated measures (22.2 %) and time to HRQoL score deterioration (18.5 %). For each targeted
dimension, the results for each group, the estimated effect size and its precision were clearly reported in 4 studies
(14.8 %), not clearly reported in 11 studies (40.7 %) and not reported at all in 12 studies (44.4 %).
Conclusions: This review demonstrated the weakness and the heterogeneity of the measurement, analysis, and
reporting of HRQoL in phase III advanced NSCLC trials. Precise and uniform recommendations are needed to
compare HRQoL results across publications and to provide understandable messages for patients and clinicians.
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Background
The Food and Drug Administration (FDA) considers
overall survival (OS) benefit as the foundation for the
approval of new anticancer drugs in the United States
[1]. Nevertheless, the increasing number of effective sal-
vage treatments available in many types of cancer (i.e.
subsequent lines of treatments) has resulted in the need
for a larger number of patients to be included and/or
the need of a more prolonged observation period to at-
tain sufficient events that can achieve planned statistical
power; this increases the cost of clinical trials and re-
quires a longer duration to obtain results [2]. Conse-
quently, intermediate endpoints such as progression-free
survival are often used as primary endpoints because
they are assessed earlier. However, there is a lack of
consistency in their definitions [3] and they are not sys-
tematically validated as surrogate endpoints for OS.
In this context, HRQoL could constitute an alternative
endpoint. HRQoL is recognized as a endpoint for cancer
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therapy approvals by the American Society of Clinical
Oncology and the FDA [1, 4] HRQoL reflects the
patient-perceived evaluation of one’s health, including
physical, emotional, and social dimensions as well as
symptoms due to disease or treatment. Several publica-
tions have underlined some key issues regarding the het-
erogeneity of HRQOL reporting in randomized clinical
trials (RCTs) in oncology [5, 6]. Moreover, the statistical
longitudinal analysis of HRQoL remains unstandardized
which compromises the comparison of results between
trials [7]. To improve the reporting of HRQoL in oncology
randomized clinical trials, an extension to the CONSORT
statement regarding HRQoL reporting was published.
Nevertheless, these guidelines do not detail the method-
ology of statistical analysis of HRQoL. Claassens et al. re-
ported that some aspects of HRQoL reporting (missing
HRQOL data, a priori hypotheses of HRQOL, rationale
for instruments used) remain underrepresented in non–
small-cell lung cancer (NSCLC) RCTs [6].
The aim of this review was to evaluate the three major
steps of HRQoL analysis: measurement, statistical ana-
lysis, results presentation in phase III clinical trials of
first-line chemotherapy in advanced NSCLC with a spe-
cial focus on the statistical analysis.
Methods
Search strategy and Selection for studies
Eligible trials were randomized phase III trials of first-
line chemotherapy in advanced NSCLC. Literature
searches in PubMed database (January 2008 to Decem-
ber 2014) were performed. Trials published from 2008
were included to assess HRQoL analysis in recent trials.
For PubMed database research, the following strategies
were used: (lung neoplasm[MeSH Terms]) AND (advan-
ced[Text Word] OR metastatic[Text Word]) + filters
Clinical Trial, Phase III. In case of companion papers
(i.e. HRQoL analyses reported in a separate paper, not in
the princeps one), only the information and method-
ology declared in the HRQoL paper were reported.
Data extraction
Two authors (F. F., A.A) independently extracted infor-
mation using predefined data abstraction forms. All data
were checked for internal consistency, and disagree-
ments were resolved by discussion among the investiga-
tors. The following details were extracted: general items
(number of patients, year of publication, study period,
number of centers, nationality of the first author, aca-
demic, mixed or industrial trial), name of the primary
endpoint, items related to HRQoL measurement and
reporting (rational for HRQoL assessment, methods of
data collection, HRQoL questionnaire, evidence of
HRQoL questionnaire validity, method/algorithm for scor-
ing the questionnaire, planned schedule of questionnaires
administration, results from each targeted dimensions for
multidimensional questionnaires, method for results pres-
entation, discussion of limitations and implications for
generalizability and clinical practice.
We assessed statistical HRQoL analysis according to
13 key parameters: statement of the targeted dimensions,
statement of the HRQoL hypothesis, procedure to con-
trol the type I error rate, statement of the minimal
clinically important difference (MCID), data set for
HRQOL analyses, description of the number of HRQoL
data available at baseline and at subsequent time points,
statement of HRQoL scores at baseline for each group
and each dimension, profile of missing data at baseline,
statement of statistical approaches for dealing with miss-
ing data, statistical approach for HRQoL analysis, MCID
taken into account in the statistical analysis method
and/or in the interpretation of the results, statement of
the multivariate analysis. Each key point was coded as
“yes” (2 points), “unclear” (1 point) or “no” (0 point). A
score on a 0–26 scale was then created with a high score
represent a high methodological level for statistical
analysis.
Data analyses
We conducted a descriptive analysis of selected publica-
tions, HRQoL measurement, reporting and of the statis-
tical analysis of HRQoL with each key point.
Quantitative variables were descripted with median and
range. Qualitative variables were descripted with absolute
frequencies (number) and relative frequencies (proportion).
Analyses were conducted with the use of SAS soft-
ware, version 9.3 (SAS Institute).
Results
HRQoL measurement
A total of 55 phase III advanced NSCLC trials published
between 2008 and 2014 were identified (Fig. 1). Among
these studies, 27 trials were identified with HRQOL end-
point (49 %) (Fig. 1) including 2 studies with HRQOL as
primary endpoint. Of the 27 studies, the background
and rationale for HRQoL used was provided in 6 trials
(22.2 %). For 5 trials (18.5 %), additional HRQoL publi-
cations were released in a separate HRQoL dedicated
paper. Five trials (18.5 %) provided no result of HRQoL.
The EORTC Quality of Life Questionnaire C30 (QLQ-
C30) was the most frequently used instrument. It was
used in 13 (48 %) of the studies (Table 1). The lung
cancer-specific module EORTC QLQ-LC13 was added
to the QLQ-C30 in 12 studies (37 %). Among these 12
studies, two studies added the EuroQoL EQ-5D generic
questionnaire to the QLQ-C30 and QLQ-LC13. The
Functional Assessment of Cancer Therapy (FACT) ques-
tionnaires were used in 12 studies (44.4 %): one study
(3.7 %) used the FACT-General (FACT-G), 7 studies
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(25.9 %) used the FACT-L questionnaire specific for lung
cancer patients and 4 studies (14.8 %) used the FACT-
LCS which is a subset of the FACT-L with 7 items
(Table 1). The Lung Cancer Symptom Scale question-
naire was used in 1 study (3.7 %). One study did not spe-
cify the HRQoL questionnaire used. The reference of the
HRQoL instrument validation was provided in 13 studies
(48 %). Among the 4 studies using the FACT question-
naires in other than English version, none of them re-
ported the transcultural validation. Six studies (22.2 %)
defined the procedure of questionnaire completion (i.e.
paper and pencil, electronic completion, at home or at
the clinic). The planned schedule of HRQoL assessment
was reported in 23 trials (85.2 %).
Statistical analysis of HRQoL
The Table 2 summarized the quality of statistical analysis
of HRQoL.
The mean score based on the 13 key parameters of the
27 trials was 6.3 (standard deviation = 6.1, range = 0-20).
The targeted dimensions of HRQoL were pre-
specified in 13 studies (48.1 %) in the method section:
6 of them used EORTC questionnaires and 7 used
FACT questionnaires. Among the 6 studies which
used EORTC questionnaires, 3 dimensions were tar-
geted in mean and targeted dimensions were dyspnea
(66.6 %), global health status (66.6 %), pain (50.0 %),
fatigue (50.0 %), cough (33.3 %) and nausea/vomiting
(33.3 %) (Table 1). Among the 7 studies which used
FACT questionnaires, 2 dimensions were targeted in
mean and most frequent targeted dimensions were the
lung cancer subscale (57.2 %), the trial outcome index
(57.2 %) and the FACT-L global score (28.6 %) (Table 1).
Nine studies (33.3 %) defined the MCID. Among these
studies: 5 used the EORTC questionnaires and all of
them used a 10-point decrease in the HRQoL scores as
the MCID (Table 1), 4 used the FACT questionnaires
and all of them used 6 points decrease for the FACT-L
global score and trial outcome index, and 2 points de-
crease for the lung cancer subscale as the MCID.
The MCID was taken into account in the statistical
analysis and/or in the interpretation of the results in 7
studies (25.9 %) (Table 1).
Only three studies mentioned the population data set
for HRQoL analysis: 2 in modified intention-to-treat, 1 in
intention-to-treat. Definition for the mITT population
were 1) “all randomly assigned patients with data were in-
cluded” [8] and 2) “patients with a baseline and at least
one post-baseline HRQoL assessment were included” [9].
The number of HRQoL data at baseline and at subse-
quent time points, the HRQoL scores at baseline for each
group and each dimension, the profile of missing data at
baseline, the statistical approaches for dealing with miss-
ing data were adequately reported in 7 (25.9 %), 6
(22.2 %), 1 (3.7 %) and 5 (18.5 %) studies, respectively
(Table 2). The statistical methods for dealing with missing
data were different (Table 1). No study provided the rea-
sons why data were missing.
Fourteen studies (51.9 %) described the statistical ap-
proach to analyze HRQoL data in the method section
(Table 2). Seven studies used two or more statistical ap-
proaches. The different statistical methods/analyses
were: the mean change from baseline (33.3 %), the linear
mixed model for repeated measures (LMM) (22.2 %),
time to HRQoL score deterioration (TTD) (18.5 %),
AUC (7.4 %), mixed-effects growth-curve model (7.4 %),
distribution of patients whose symptom had improved,
remained stable or worsened (3.4 %), Fisher test for
equal proportion of patients achieving at least two
points increase (3.4 %), group comparisons of scale at
each time (3.4 %), rates of symptom palliation (3.4 %),
percentage of patients with at least two points improve-
ment at the beginning of the cycle two (3.4 %) (Table 1).
No study specified which were the primary statistical
analysis and the sensitive analysis.
Among the six studies which used a LMM to analyze
the longitudinal HRQoL data, none of them declared the
Records identified through 
Pubmed search 
(n=248)
Full articles assessed for 
eligibility: 55 randomized phase 
III trials of first-line 
chemotherapy in advanced
NSCLC 
Records excluded (n=193) :
- Not first line of chemotherapy 
(n=58)
- Biomarker studies (n=32)
- Radiotherapy trials (n=16)
- Protocols (n=11) 
- Subgroup studies (n=14)
- Retrospective studies (n=8)
- Others (n=54)
Studies included in qualitative 
analysis: 27 randomized phase 
III trials of first-line 
chemotherapy in advanced 
NSCLC with health-related 
quality of life as endpoint
Full articles excluded: 28 randomized 
phase III trials of first-line 
chemotherapy in advanced NSCLC 
without health-related quality of life 
as endpoint
Records screened
(n = 248  )
Fig. 1 Identification randomized phase III trials of first-line
chemotherapy in advanced non-small cell lung cancer (NSCLC)
trials from PubMed search
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Table 1 Aspects relevant to HRQoL statistical analysis
First authors HRQoL questionnaire Timing of assessment Targeted dimensions MCID Statistical approach for
dealing with missing data
Statistical approach for HRQoL
analysis
Wu [19] QLQ-C30; QLQ-LC13 Randomization and every 3
weeks until disease progression
or new cancer treatment
Cough, dyspnoea,
pain
10 points Distribution of patients whose
symptom had improved,
remained stable, or worsened;
the time to deterioration of
symptoms; mixed-effects
growth curve model




At baseline and every cycle
Yang [7] QLQ-C30; QLQ-LC13 Random assignment and every
21 days until disease progression
Cough, dyspnoea, pain 10 Joint analysis Time to deterioration; mixed-
effects growth curve model
Wu [19] FACT-L Not available FACT-L total score
and TOI
Time to deterioration
Yoshioka [21] FACT-L; FACT/GOGNTX At the time of enrollment and at
6 and 9 weeks after the initiation
of treatment
Linear mixed model for
repeated measures
Lee [22] QLQ-C30, QLQ-LC14,
EUROQOL
Baseline, monthly during the
first year, then 18 and 24 months
after randomization
Linear mixed model for
repeated measures
Gridelli [23]
Flotten [24] QLQ-C30, QLQ-LC13 Before each cycle, 3 weeks after
the last cycle, and then every 8
weeks until 57 weeks
Global health status health,
nausea/vomiting, dyspnoea,
fatigue
10 Mean change from baseline




Mean change from baseline
Groen [26] QLQ-C30, QLQ-LC13 Start of chemotherapy and
weeks 6,12,16,24,30
Mean change from baseline
Chen [9] FACT-L Baseline and every 6 weeks 6 for FACT-L total score
and TOI; 2 points for
LCS LCS
Mean change from baseline
Lara [27] QLQ-C30 On day 1 of each odd cycle and
at the end of the treatment visit
Mean change from baseline
Koch [12] QLQ-C30, QLQ-LC13 Baseline, weeks 3,6,9,12,20,28 Dyspnoea, fatigue, pain,
pain medication, global
health status
Group comparisons of scale at
each time; mean change from
baseline; AUC; rates of symptom
palliation
Biesma [28] QLQ-C30, QLQ-LC13 Before, during (day 1 and day 8
of each cycle) and after each
cycle (weeks 12,15,18)
Global health status 10 Mean change from baseline and











Table 1 Aspects relevant to HRQoL statistical analysis (Continued)
Weissman
[29]
FACT-L After each cycle TOI Mean change from baseline
and after 6 cycles
Okamoto
[30]
FACT-L, FACT/GOGNTX Time of enrollment and at 6
and 9 weeks after initiation of
treatment




FACT-L Baseline, weeks 1 AND 3, 3-
weekly until week 18, 6 weekly
until progression and at
discontinuation
FACT-L Score, TOI, LCS 6 for FACT-L total score
and TOI; 2 points for
LCS
If less than 50% of the Fact-l
subscale scores were missing,
the subscale score was divided
by the number of completed
items and multiplied by the
total number of items on the
scale. If 50% or more of the
items were missing, that
subscale was treated as missing
for that patient
Mean change from baseline;
Time to worsening; Time to
improvement
Lynch [32] FACT-L Baseline, before each treatment
cycle and at the end of the
therapy
Mean change from baseline;
Time to symptomatic disease
progression
Takeda [33] FACT-L The time of enrollment and at
12 weeks, 18 weeks after
initiation of treatment
LCS Linear mixed-effects model in
which the missing data depend
on the observed score
Linear mixed model for
repeated measures
Lee [34] QLQ-C30, QLQ-LC14 Random, During each cycle, at
the end of the chemotherapy,
every 6 months until 24 months
Linear mixed model for
repeated measures
Treat [35] FACT-L Not available
Tan [36] Lung cancer symptom
scale
Baseline, at the end of each cycle,
just before the next cycle, at the
end of the study





QLQ-C30, QLQ-LC13 Weeks 0,3,6,9,12,20,28,36,44,52 Global health status health,
nausea/vomiting, dyspnoea,
fatigue
10 Last value carried forward for
missing value that followed,
even after death
Area under the curve
O’Brien [39] FACT-L Baseline, before each cycle and
at the end of the treatment
LCS 2 Missing scores at week 3 were
classified as having less than a
2-point increase in the primary
analysis data but classified as
missing and excluded from the
supplemental analysis
Fisher test for equal proportion
of patients achieving at least
two points increase
Langer [40] FACT-L Baseline and within 3 days of
each treatment
LCS 2 Percentage of patients with at
least two points improvement
at the beginning of cycle 2










effects introduced in the model (random or fixed effects
and interactions).
One study presented a multivariate analysis (Table 2).
HRQoL results presentation
For each targeted dimension, the results for each group,
the estimated effect size and its precision were ad-
equately reported in four studies (14.8 %), not clearly re-
ported in 11 studies (40.7 %) and not reported at all in
12 studies (44.4 %). A discussion specific limitations and
implications for clinical practice was provided in 10 arti-
cles (37 %) (Table 1).
The results were presented in the text, figures or tables
in 24 (88.9 %), 12 (44.4 %) and 8 (29.6 %) articles, re-
spectively (Table 1).
Discussion
In this review, we showed that HRQoL was declared as
an endpoint in only 49 % of the phase III clinical trials
in advanced NSCLC published between 2008 and 2014.
Moreover, we clearly demonstrated the heterogeneity
and the weakness of the methodology of HRQoL meas-
urement, statistical analysis and reporting. First, two
questionnaires are the most widely used: the QLQ-C30
plus LC13 module (48 %) and the FACT-L (44 %). As an
example, the OPTIMAL [8, 9] and the Lux-Lung 3 [10]
trials compared the efficacy and tolerability of two tyro-
sine kinase inhibitor (erlotinib and afatinib, respectively)
versus chemotherapy in first-line line treatment of pa-
tients with advanced EGFR mutation-positive NSCLC.
HRQoL was assessed by the FACT-L questionnaire in
OPTIMAL trial [9] while EORTC QLQ-C30 and LC13
module were used in LUX-Lung 3 trial [7]. These two
clinical trials could hardly be compared since EORTC
and FACT questionnaires for lung cancer do not contain
the same dimensions in regard to impact of lung cancer
on HRQoL. Moreover, two studies used the EuroQoL
EQ-5D generic questionnaire which comprises only five
short questions and is suitable since it limits patient bur-
den and in that way also encourages response rate.
Nevertheless this questionnaire has not been tailored to
the special requirements of patients with cancer. At this
time, the foremost challenge would be to promote,
through cancer site and treatment modalities, guidelines
for selecting the best questionnaires allowing for direct
comparison of results across trials. Moreover, it is also
still necessary to develop some new tools to evaluate
HRQoL. Already validated questionnaires may not be
adapted to new targeted biotherapy agent which can in-
duce some long-term moderate toxicities.
Then, the number of HRQoL measures and intervals
between two consecutive measures vary from one study
to another. HRQoL is often captured until tumor pro-
gression, nevertheless, in advanced NSCLC, we could
wonder if it would be more appropriate to measure
HRQoL until death. Recommendations on the schedule
of HRQoL assessment should be provided. At least three
HRQoL assessment are recommended: at baseline, dur-
ing treatment and at the end of the study (http://group-
s.eortc.be/qol/eortc-qlq-c30). However, a more intensive
HRQoL assessment is preferable to better capture the
longitudinal trajectory of HRQoL level and to capture
any relevant changes. In this review, most of studies
evaluate HRQoL at baseline and then every treatment
cycle which allow a good appreciation of the impact of
treatment of HRQoL over time, but it depends on the
number of cycles received by the patient. Moreover at-
tention should be paid to the timing of diagnostic proce-
dures which could influenced HRQoL results, especially
with lifethreatening cancers. Patients are likely to be
Table 2 The 13 keys parameters for statistical HRQoL analysis assessed as “yes” if the authors specified the parameter, “not clear” it
was not clear and “no” if the authors didn’t specify the parameter
Yes, n (%) Not clear, n (%) No, n (%)
Targeted dimensions 13 (48.1) 0 14 (51.9)
HRQoL hypothesis 2 (7.4) 0 25 (92.6)
Procedure to control the type I error 1 (3.7) 1 (3.7) 25 (92.6)
Minimal clinically important difference 9 (33.3) 1 (3.7) 17 (63)
Study population 3 (11.1) 3 (11.1) 21 (77.8)
Number of HRQoL data at subsequent time points 7 (25.9) 6 (22.2) 14 (51.9)
HRQoL scores at baseline for each group and each dimension 6 (22.2) 2 (7.4) 19 (70.4)
Profile of missing data at baseline 1 (3.7) 2 (7.4) 24 (88.9)
Statistical approaches for dealing with missing data 5 (18.5) 0 22 (81.5)
Statistical approach for HRQoL analysis 14 (51.9) 1 (3.7) 12 (44.4)
MCID taken into account in the statistical analysis 7 (25.9) 2 (7.4) 18 (66.7)
Multivariate analysis 1 (3.7) 0 26 (96.4)
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experiencing stress in anticipation of the yet unknown
results. After the procedure, the patients will either be
experiencing great relief or anxiety depending on the re-
sults. This point should be taken into account in HRQoL
assessment design and be carefully documented in the
protocol and emphasized during training.
The a priori selection of the targeted dimensions was
heterogeneous between the trials and was pre-specified
only 13 times (48.1 %) in the method section and most
of them are symptomatic scales. We know that there is
general agreement concerning the multidimensional
concept of HRQoL taking into account levels of physical,
mental, social, and patient satisfaction with treatment.
Therefore, the choice of only symptomatic HRQoL di-
mensions reaches the problem of the holistic sense of
HRQoL. Moreover, the choice of the targeted dimensions
of HRQoL must be discussed between clinicians and
methodologists and clearly described in the protocol.
In confirmatory clinical trials with multiple endpoints,
the use of multiple test procedures is mandatory and
CONSORT Statement recommends a multiplicity ad-
justment in case of multiple testing [11]. However, only
one study clearly stated the procedure to control the
type I error [12].
Prior to longitudinal HRQoL data analysis, the MCID
should be a priori determined [13]. In our review, only
nine studies (33.3 %) clearly specified it. The MCID rep-
resents the smallest changes/differences in HRQoL
score, which is perceived as clinically important. For the
EORTC questionnaires, a 5-point to a 10-point differ-
ence in scores could be considered as the MCID [14]. In
patients with NSCLC, Maringwa et al. [15] tried to de-
termine the smallest changes in HRQOL scores in a sub-
set of the EORTC QLQ-C30 scales, which could be
considered as clinically meaningful. They concluded that
the estimates of 5 to 10 units of the QLQ-C30 scales
may be used as guidance for clinicians and researchers
to classify patients as improved or deteriorated. In our
review, the 5 studies which used the QLQ-C30 and
stated the MCID, all used a 10-point decrease in the
HRQoL scores as the MCID. A sensitivity analysis, with
a MCID of 5 points could have been proposed to assess
the robustness of the results.
Missing data, considered as missing not at random,
can bias the longitudinal analysis if it is not adequately
taken into account [16]. Patients may drop out before
the planned end of the study, resulting in the absence of
any available HRQoL data after the patient’s drop out
(i.e. attrition). Moreover, drop out occurs generally due
to a deterioration of patient health status or death. Pa-
tients may also be too tired to fill the questionnaire en-
tirely at a specific measurement time. This induces the
potential risk to select subpopulation of patients with
better HRQoL levels and with available HRQoL data.
Not adjusting for missing data can limit the robustness
of the results and the confidence in the HRQoL conclu-
sions. Therefore, the profile of missing data at baseline
and the number of HRQoL at subsequent time points
for each group must be specified. In our review, these
two information were reported in only 1 (3.7 %) and 7
(25.9 %) trials, respectively. Furthermore, only 5 studies
(18.5 %) described the statistical approaches for dealing
with missing data and the 5 methods were different.
Thus, the reporting of missing data and the statistical
approaches of analysis of missing data need to be
standardized.
There are a number of possible ways of analyzing lon-
gitudinal HRQoL data. Currently, the two main robust
methods are: the LMM and the TTD [6, 17]. In our re-
view, the most widely used is the mean change from
baseline (33.3 %). This method summarizes the longitu-
dinal data into a summary statistic before performing a
between-arms comparison. This method is rather simple
but may overlook important changes in HRQoL along
time and should not be applied. This method is not a
model of longitudinal analysis. The LMM method was
used in 6 studies (22.2 %). In all these studies the fixed
effects, the random effects and the correlation matrix
between HRQoL measures introduced in the model were
not specified. Thus, results are very difficult to interpret.
The LMM can estimate a time effect, an arm effect and
an interaction between treatment arm and time (reflect-
ing a different evolution of the two treatment arms over
time). The LMM contains both fixed effects (reflecting
average trends) such as treatment and random effects
(individual trends). This model accounts for the associ-
ation (i.e. correlation) of measures made on the same
patient at different times.
Finally, the LMM model generally require a normally
distribution of the score studied. All studies using this
method did not mention this hypothesis and a priori did
not check it. For EORTC questionnaires, scores gener-
ally do not respect a normal distribution due to the low
number of items per dimension. The TTD approach was
used in 5 studies (18.5 %). Currently the definition of the
TTD is not standardized; therefore the studies must
clearly define it. The definition of the TTD must include:
reference score, the event of interest, the censoring
process, including death or not [6]. In our review, only
one study defined the TTD: “Time to deterioration in
patient-reported outcomes was measured in months
from random assignment to the first instance of symp-
tom worsening (10 points from baseline). Patients with-
out worsening, including those with disease progression,
were censored at the last available patient-reported out-
come assessment; those lacking post-baseline assessments
were censored at random assignment. Patients who died
without documented worsening were considered to have
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deteriorated at the time of death” [7]. Other statistical
methods were used: “distribution of patients whose symp-
tom had improved, remained stable or worsened”, “Fisher
test for equal proportion of patients achieving at least two
points increase”, “group comparisons of scale at each
time”, “rates of symptom palliation”, “percentage of pa-
tients with at least two points improvement at the begin-
ning of the cycle two”. These methods can guide on the
choice of the most appropriate analytical method to use to
analyze longitudinal HRQoL data (e.g., the LMM or the
TTD) approach. However, these analyses alone cannot be
sufficient to capture all information present in the longitu-
dinal HRQoL assessment and must be completed by a
longitudinal statistical approach taking into account the
correlation between HRQoL measures.
Finally, it should be acknowledged that journal space
is often limited, and authors may not have been able to
report all the methodology. Therefore, HRQoL may sys-
tematically be reported in separate HRQoL dedicated
manuscripts.
Conclusions
Our review demonstrated the poor quality and the het-
erogeneity of the measurement, analysis, and reporting
of HRQoL in phase III advanced NSCLC trials. The het-
erogeneity between trials limits their cross comparison
and the feasibility of meta-analysis.
The HRQoL CONSORT statement regarding HRQoL
reporting was published in 2013 [18] and it is true that
we reviewed studies published before 2013. The use of
the HRQoL CONSORT extensions should be encour-
aged. Nevertheless, these guidelines do not detail the
methodology of statistical analysis of HRQoL. Incom-
plete or inaccurate statistical analysis of HRQoL can
affect the reliability of these outcomes. Therefore, devel-
opment of guidelines for longitudinal HRQoL analysis of
clinical trials is important to facilitate interpretation of
HRQoL findings.
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